by MASC-Admin | Jul 11, 2018 | Current News
Second-line avelumab treatment of patients with metastatic MCC: Experience from a global expanded access program (EAP);John Walker et al. A poster presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting presented data on second-line...
by MASC-Admin | Jul 11, 2018 | Current News
Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic MCC progressed on chemotherapy;Paul Nghiem et al. At the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr Suzanne Topalian (John...
by MASC-Admin | Jul 11, 2018 | Current News
Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic MCC progressed on chemotherapy;Paul Nghiem et al. At the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr Paul Nghiem (University...
by MASC-Admin | Jul 11, 2018 | Current News
Durable tumor regression and OS in patients with advanced MCC receiving pembrolizumab as first-line therapy;Paul Nghiem et al. At the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr Paul Nghiem (University of Washington) presented data on patients...
by MASC-Admin | Apr 4, 2018 | Current News
“On Friday 1st June 2018, Merck/Pfizer announced that the current BAVENCIO (avelumab) metastatic Merkel cell carcinoma access program in Australia will be closed. Any patient request already approved on the access program was grandfathered on Friday, 1st June, and...
Recent Comments